Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

5,934.00GBp
19 Oct 2018
Change (% chg)

56.00 (+0.95%)
Prev Close
5,878.00
Open
5,902.00
Day's High
5,956.00
Day's Low
5,869.00
Volume
1,815,486
Avg. Vol
1,818,024
52-wk High
6,126.40
52-wk Low
4,544.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 30.90 33.64
EPS (TTM): 2.34 -- --
ROI: 7.86 14.75 14.27
ROE: 28.47 16.24 15.99

AstraZeneca's Lynparza shown to put brakes on ovarian cancer

MUNICH An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.

21 Oct 2018

AstraZeneca's Lynparza shown to put brakes on ovarian cancer

MUNICH, Oct 21 An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class.

21 Oct 2018

Beset by copies, Roche gets sales boost from China

ZURICH Roche's third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries.

17 Oct 2018

Beset by copies, Roche gets sales boost from China

ZURICH Roche's third-quarter revenue beat analysts' forecasts as new drugs such as Ocrevus for multiple sclerosis picked up pace and as China bought more of older medicines whose sales are dropping elsewhere following patent expiries.

17 Oct 2018

UPDATE 2-Beset by copies, Roche gets sales boost from China

* CEO Schwan's bet on new drugs paying off (Adds comments about China, CEO and analyst quote)

17 Oct 2018

AstraZeneca will keep UK investment freeze if no Brexit clarity

PARIS AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday.

15 Oct 2018

AstraZeneca will keep UK investment freeze if no Brexit clarity

PARIS AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday.

15 Oct 2018

UPDATE 2-AstraZeneca will keep UK investment freeze if no Brexit clarity

* Drugmaker already stockpiling medicines (Recasts, adds AstraZeneca comment)

15 Oct 2018

AstraZeneca halts UK investments due to Brexit uncertainties - Le Monde

PARIS, Oct 15 AstraZeneca has suspended investments in Britain due to the lack of clarity over the country's departure from the European Union, the pharmaceutical firm's non-executive chairman Leif Johansson told France's Le Monde newspaper.

15 Oct 2018

UPDATE 1-Novo Nordisk hires AstraZeneca executive to revive struggling biopharma unit

COPENHAGEN, Oct 15 Novo Nordisk is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit.

15 Oct 2018

Earnings vs. Estimates